trending Market Intelligence /marketintelligence/en/news-insights/trending/tmd2cwsgsqlronqu45bz3q2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Portola secures $50M loan from Bristol-Myers Squibb, Pfizer

L.K. Bennett: Bankruptcy Case Study

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry


Portola secures $50M loan from Bristol-Myers Squibb, Pfizer

Bristol-Myers Squibb Co. and Pfizer Inc. are lending $50 million to Portola Pharmaceuticals Inc. to help advance AndexXa, the company's potential antidote for Factor Xa inhibitors.

Bristol-Myers and Pfizer will each loan $25 million, the principal and interest of which will be repaid through royalties on AndexXa's commercial sales.

Portola is targeting regulatory approval of the drug in 2017, which is currently ongoing phase 3b/4 in patients with Factor Xa inhibitor-associated acute major bleeding.

Bristol-Myers Squibb and Pfizer have been collaborating with Portola Pharmaceuticals on the drug in exchange for rights in certain countries.